Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also good to be mentioned in Pharma related journals.
May even help towards the long term plans????
"(2) During the period of the drug research and development agreement, Provexis and the company will cooperate in drug research and development projects in accordance with the terms of this agreement, and the company has the exclusive right to develop drugs in the area under the agreement."
http://data.eastmoney.com/notices/detail/300146/AN202111051527225504.html
Provexis and By-Health will seek to collaborate on research and development projects which may result in the development and approval of Fruitflow as a drug, for potential sale and distribution in the Territories.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1523432
P.S. Nice rise in B-H share price today. Showing 9.34%
Good to be regarded as a successful product.
Another Mention in the pharma world
https://www.sciencedirect.com/science/article/abs/pii/S1043661821005855
https://www.google.co.uk/search?q=fruitflow%22The+current+use+and+evolving+landscape+of+nutraceuticals%22
2
4 Nov 2021 — The Current Use and Evolving Landscape of Nutraceuticals ... One such example of a successful product is Fruitflow® manufactured by Provexis ...
to be published in a pharma journal next month
https://www.sciencedirect.com/journal/pharmacological-research
About the journal
Formerly known as Pharmacological Research Communications;
Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. We provide a venue through which specialists across disciplines can rapidly exchange information in health sciences that pertains to modern …
https://dysw-cnki-net.translate.goog/kcms/detail/detail.aspx?filename=1021699508.nh&dbcode=CMFD&dbname=CMFDTEMP&v&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en
Find the ‘more’ to extend to full text.
Barbershop,
RE: but it wouldn't rule out us buying from DSM and them handling logistics to ship to China
Although a possibility I don't think that is the plan.
"The Agreement for Fruitflow announced today between the Company and By-Health falls under (ii) above, with the Company set to sell Fruitflow as an ingredient directly to By-Health from 1 January 2023; 100% of the Company's sales of Fruitflow to By-Health will accrue directly to the Company, and the Company will retain all of the resulting profits."
The company (PXS) is already in negotiations with the third party manufacturers.
"The Company and the third party manufacturers are actively engaged in some ongoing production capacity planning, looking at the steps required to scale-up the production of Fruitflow to meet the anticipated increase in demand."
Its a win win situation for Provexis and probably for By-Health as well as we could supply them with a cheaper product price and still come out with a higher profit.
Just in my opinion though.
Alf, how does my post suggesting that we could buy FF from DSM say that we would manufacture it ourselves?
DSM manufacture is what I'd said at the time. That might not add up as DSM don't manufacture as Gixer pointed out, but it wouldn't rule out us buying from DSM and them handling logistics to ship to China.
At no point did I suggest we manufacture ourselves....not sure why you want to drag that point out when what you claim is clearly untrue.
Its a good guess and we can only assume that it was for Team DSM and we received £9.2k for the Fruitflow+ nitrates development products in the year so it must have been a few packs :)
Again, only assuming but Fruitflow + Nitrates would be outside the Alliance Agreement.
That would make sense..... The Jan 21 interims do not indicate the nitrates were for the cycling team though. Doesn't really matter, all good progress..
From Jan 21 interims
Further interest in the role of Fruitflow in exercise has been generated by pro cycling Team DSM (formerly Team Sunweb)'s use of Fruitflow in the Tour de France. The benefits that Fruitflow can provide for athletes in terms of improved recovery are set out in more detail on the website at www.fruitflowplus.com/sportrecovery.
The Company continues to work on a potential Fruitflow+ nitrates product which would be supported by the Company's strong patent position in this area, with the involvement now of third party manufacturers and with some interest already generated from brand owners. The product will have anti-inflammatory and circulation benefits for athletes seeking to recover after exercise, properties which would also be potentially beneficial to a wide range of other consumers to include people who are less active and people who suffering from the symptoms of basic ageing.
Could it be what the cycling lads were taking?
I found this statement in the results intriguing
"In collaboration with DSM a trial batch of Fruitflow+ nitrates development products was manufactured during the year and sold to DSM."
Who did the selling ? Did DSM sell to itself ? Who supplied the nitrates ? SiS ?
W?
Yep, although I doubt anyone here has been invested from the formation of Provexis.
Your Sunday 12.03 post does say exactly that, and even suggests a mark up, I think that's why myself and gixer sought to clarify. All makes zero difference to the outcome, that's be down to the completion of studies and what effect they have on the opinions of health professionals. If there can be a proven link to aiding recovery from Covid symptoms, then Wellsite's comment that Fruitflow may be too big for Provexis to handle may well be highly viable IMHO
Well to be fair Alf, I'd never said we should be responsible for the manufacturing side, and that's what you seemed to be suggesting I had said.
Fair enough if we see things in a different way, but at least try to deal with people's opinions rather than things they haven't said.
Not sure why BB is taking umbridge though, just a few people bored senseless, having a chat after 15+ years of waiting...
..and all I said was it seemed an illogical position.
Polish that badge BB
:-)
Strange the links didn't work so try this.
https://bit.ly/3EsCCmZ
https://bit.ly/3xZPYV3
Evaluation of the equivalence of different intakes of Fruitflow in affecting platelet aggregation and thrombin generation capacity in a randomized, double-blinded pilot study in male subjects.
https://bm****r.biomedcentral.com/articles/10.1186/s40795-021-00485-5
Peer Review reports
https://bm****r.biomedcentral.com/articles/10.1186/s40795-021-00485-5/peer-review
BB,
"negative" no
"paranoid" no
But if Barbershop, or anyone else, feels like I have jumped down his/her throat because I simply disagreed with there statement then I apologise. It was not my intention to come across that way.
As we have already agreed to disagree I am unsure why you feel the need to bring it up again but my opinion, rightly or wrongly remains the same.
As Provexis is responsible for the manufacture, supply and sale of Fruitflow to By-Health I don't see how they can be classed as the middleman.
Does it matter either way? No.
Seems to me that some people are jumping down a poster's throat because they perceived the term "middleman" as negative and took umbrage at that.
If you own the IP, and act as a middleman, that's actually acknowledging your limitations and, almost certainly, maximising your returns. But if you're a bit paranoid about stuff posted, you might not see it like that.
See also https://dictionary.cambridge.org/dictionary/english/middleman
BB
lol, BH would own the IP by then
W£
Allowing the Chinese to produce their own is laying PXS open to be defrauded imo. Everyone knows just how much IP they have stolen already . Look at KETL they spend millions suing those that nick their IP.
Fair enough.
Hopefully next few years will start to see some kind of turnaround in outlook.
Well we will have to agree to disagree on this one.
As for "salting it", I am only stating how I see it.
One thing that is for sure is all the profit will go directly to Provexis from By-Health sales, not split with DSM and there share would have been more than 10%
No one mentioned or suggested generics Gixer, we all know we're talking about FF and that we have patent protection.
Not sure why you and Alfista can't respond to what people are saying without salting it.
This is what I'm seeing from Provexis scope:
manufacturer (3rd party) >>supplier(Provexis)>>Customer(ByHealth)
Seems to put us in the middle.
You might well say that ByHealth then sell on again in various formats, but it's outside our scope in the terms of the supply chain.
I thin that would be bad practice, as it would hand too much control to BH, making it difficult for to separate at the end of the agreement/contract term. Much better if PXS maintain production control and use a third party to produce it. Also they will benefit from economies of scale. Stephen Moon once said that with increased production, the margin goes from good to very high.
Longer term I expect By Health shall set up their own in country FF production
- makes sense as China is the biggest tomato producer
https://edis.ifas.ufl.edu/publication/FE1027
W$
Fruitflow is currently produced by outsourced third party manufacturers in Europe, and it is intended that the Company will have direct access to these manufacturers for its sales of Fruitflow to third parties. The Company and the third party manufacturers are actively engaged in some ongoing production capacity planning, looking at the steps required to scale-up the production of Fruitflow to meet the anticipated increase in demand.